Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Adam Sperling, MD, PhD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, about the rationale to evaluate cellular therapy in multiple myeloma.
Sperling discussed how the disease biology of multiple myeloma has demonstrated clear involvement with the immune system, and immune escape is an important feature of the malignancy. As such, immune- and cellular-based therapies have been a cornerstone of treatment in this setting, Sperling adds.
In addition, myeloma plasma cells express BCMA almost universally, Sperling says. Moreover, BCMA is not present on normal cells, making it an optimal target for therapies, Sperling concludes.
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL
December 7th 2024In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.
